Condition: Non-Small Cell Lung Cancer · RET Driver Mutation · BRAF V600 Mutation · Sponsor: Guangdong Provincial People's Hospital
Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.
This description comes directly from the study's public registry record.
Wen-Zhao Zhong, Ph.D · +86 02083827812 · syzhongwenzhao@scut.edu.cn
Rui Fu, Ph.D · +86 02083827812 · ruifu66@foxmail.com
Always discuss trial participation with your own doctor first.
| Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences | Guanzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05800340